STUDY OF VASCULAR ENDOTHELIUM CONDI-TION IN PATIENTS WITH UROLITHIASIS

To study the functional condition of vascular endothelium in patients with urolithiasis and to prove the feasibility of using drugs of metabolic therapy. Materials and Methods. 60 patients with urolithiasis (calcium oxalate nephrolithiasis) aged 20 to 65 (the 1st main group) were examined. The 2nd group was a control group of 25 healthy individuals of the same age with patients of the main group. The data of anamnesis were studied; an objective, instrumental and laboratory examination of patients was carried out according to the protocol. Endothelin-1 in plasma was determined by immunoassay. Statistical data processing was carried out using parametric and non-parametric methods. Results. In patients with urolithiasis, the level of endothelin-1 in serum was significantly higher (p <0.001) than in healthy people. It's value depended on the localization and size of the stone. The level of ET-1 increased with growing up of patients' age. It was the highest in patients aged 50-65 years and was 3.78±0.52fmol/ml. It can be associated with an increase number of comorbidity with age, which in turn contributes to the occurrence of more severe forms of endothelial dysfunction. The level of serum ET-1 depended on the duration of urolithiasis. The average value of the serum ET-1 parameter was 3.6 ± 0.3 fmol / ml in case of duration of the disease for more than 5 years, the endothelin level was 2.5 ± 0.2 fmol / ml at an incidence of urolithiasis from 3-4 years; and the average ET-1 was 1.4 ± 0.1 fmol / ml with the duration of the disease 1-3 years. Conclusion. An increased endothelin-1 level indicates endothelial dysfunction in patients with urolithiasis. Concentration in the blood plasma of ET-1 in these patients has already increased in the early stages of the disease formation. The elevated level of ET-1 in patients with urolithiasis and its increase with the progression of the disease may be one of the leading pathogenetic factors of the occurrence and progression of the pathological process in the kidney. This confirms the expediency of the use of drugs for metabolic action in complex therapy.